In summary, our experiments suggest that GDNF, which has been, and currently is, in clinical trials for Parkinson's disease (Kirkeby and Barker, 2019), may bear potential to serve as a prospective means to improve nephron endowment in the future. The gene discussed is GDNF; the disease is Parkinson disease.